Soleno Therapeutics Inc.
Soleno Therapeutics Announces $200 Million Public Offering of Common Stock
Summary
Soleno Therapeutics, Inc. announced on July 10, 2025, that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering, with an additional 30-day option to sell up to $30 million more. The offering is expected to close on or about July 11, 2025, subject to customary closing conditions. The net proceeds will be used to fund the commercialization of VYKAT™ XR, regulatory and market development activities in the European Union, research and development efforts, and general corporate purposes.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (4)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement